Review Article

Magnetic Resonance Spectroscopy: An In Vivo Molecular Imaging Biomarker for Parkinson’s Disease?

Table 1

Main results of MRS studies in Parkinson’s disease versus controls.

MRS techniqueNumber of PD patientsMain results versus control subjectsMean (SD) of metabolite ratios in controlsMean (SD) of metabolite ratios in PD patientsSignificant differences were indicated by the following: Reference

1HMRS at 1.5 T6Reduction of NAA/Cho ratios in the lentiform nucleusNAA/Cho:
2.11 (0.39)
NAA/Cho:
1.29 (0.28)
.[9]

1HMRS at 1.5 T15 (in 7 the symptomatic side was on the left and in 8 it was on the right)Reduction of NAA/Cr ratios in the left symptomatic side of SNNAA/Cr:
1.37 (0.22)
NAA/Cr:
1.20 (0.36)
[10]

1HMRS at 1.5 T10Increase of total Cr in the prefrontal cortexCr:
0.61 (0.16) IU
Cr:
0.76 (0.08) IU
[11]

1HMRS at 1.5 T20Reduction of NAA/Cr and Cho/Cr ratios in the temporoparietal cortexNAA/Cr:
2.06 (*)
Cho/Cr:
0.75 (*)
NAA/Cr:
1.78 (*)
Cho/Cr:
0.47 (*)
For NAA/Cr  
  
For Cho/Cr  
[12]

1HMRS at 1.5 T17Reduction of NAA/Cr ratios in the temporoparietal cortexNAA/Cr:
2.20 (0.38)
NAA/Cr:
1.78 (0.30)
[13]

1HMRS at 1.5 T10Reduction of NAA/Cr ratios in the motor cortexNAA/Cr:
1.34 (0.11)
NAA/Cr:
1.21 (0.12)
[14]

1HMRS at 1.5 T12Reduction of NAA/Cr ratios in the posterior cingulated cortexNAA/Cr:
1.78 (0.39)
NAA/Cr:
1.53 (0.20)
[15]

1HMRS at 1.5 T44Reduction of NAA/Cr ratios in the presupplementary motor areaNAA/Cr:
1.47 (0.16)
NAA/Cr:
1.39 (0.17)
[16]

3D 1HMRSI at 3 T9Reduction of NAA/Cr and mI/Cr in the rostral SN regions and increase of NAA/Cr and mI/Cr in the caudal SN regionsNAA/Crros:
3.34 (1.23)
mI/Crros:
0.82 (0.43)
NAA/Crcau:
2.03 (0.67)
mI/Crcau:
0.64 (0.34)
NAA/Crros:
2.45 (1.55)
mI/Crros:
0.59 (0.52)
NAA/Crcau:
4.92 (2.96)
mI/Crcau:
1.95 (1.43)
for NAA/Crros
for  
mI/Crros
for NAA/Crcau
for  
mI/Crcau
[21]

1HMRSI at 3 T20Reduction of NAA/Cr and Cho/Cr ratios in bilateral temporal gray matter and increase of total Cr in the right temporal gray matterNAA/Crleft:
1.27 (0.09)
Cho/Crleft:
0.18 (0.032)
NAA/Crrigth:
1.32 (0.121)
Cho/Crleft:
0.18 (0.034)
Crrigth:
1995 (225) IU
NAA/Crleft:
1.13 (0.131)
Cho/Crleft:
0.14 (0.028)
NAA/Crrigth:
1.17 (0.213)
Cho/Crleft:
0.13 (0.034)
Crrigth:
2243 (361) IU
for NAA/Crleft and Cho/Crleft
for NAA/Crright
for Cho/Crright
for Crright
[22]

1HMRS at 3 T12Reduction of Glu/Cr ratios in the posterior cingulated gyrusGlu/Cr:
0.555 (0.07)
Glu/Cr:
0.474 (0.092)
[23]

1HMRS at 4 T10Reduction of Glu, NAA, and glutathione and increase of Cho in the SN. Increase of GABA/Glu ratio in SN versus cerebral cortexNANANA[24]

1HMRS at 7 T13Increase of GABA in the pons and putamenGABApons:
1.0 (0.2) mol/g
GABAputamen:
1.6 (0.2) mol/g
GABApons:
1.6 (0.4) mol/g
GABAputamen:
2.1 (0.4) mol/g
for GABApons
for GABAputamen
[25]

Cho: choline-containing compounds; Cr: creatine + phosphocreatine; GABA: -aminobutyric acid; Glu: glutamate; 1HMRS: proton magnetic resonance spectroscopy; 1HMRSI: proton magnetic resonance spectroscopy imaging; IU: institutional units; mI: myoinositol; MRS: magnetic resonance spectroscopy; NA: not applicable; NAA: N-acetylaspartate; PD: Parkinson’s disease; SD: standard deviation; SN: substantia nigra; T: Tesla. *: DS not done.